MA50034B1 - Composition de stimulation ovarienne contrôlée - Google Patents

Composition de stimulation ovarienne contrôlée

Info

Publication number
MA50034B1
MA50034B1 MA50034A MA50034A MA50034B1 MA 50034 B1 MA50034 B1 MA 50034B1 MA 50034 A MA50034 A MA 50034A MA 50034 A MA50034 A MA 50034A MA 50034 B1 MA50034 B1 MA 50034B1
Authority
MA
Morocco
Prior art keywords
ovarian stimulation
controlled ovarian
stimulation composition
composition
fsh
Prior art date
Application number
MA50034A
Other languages
English (en)
Other versions
MA50034A (fr
Inventor
Lisbeth Helmgaard
Bjarke Mirner Klein
Saez Joan-Carles Arce
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA50034A publication Critical patent/MA50034A/fr
Publication of MA50034B1 publication Critical patent/MA50034B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des préparations contenant de la fsh, par exemple de la fsh recombinante, destinées à être utilisées dans le traitement de l'infertilité chez des patients ayant un taux élevé d'amh et un faible poids corporel.
MA50034A 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée MA50034B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (fr) 2017-09-01 2018-08-31 Composition destinée à la stimulation ovarienne contrôlée

Publications (2)

Publication Number Publication Date
MA50034A MA50034A (fr) 2021-05-12
MA50034B1 true MA50034B1 (fr) 2022-02-28

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
MA56224A MA56224B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée
MA50034A MA50034B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA56224A MA56224B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Country Status (32)

Country Link
US (2) US11744879B2 (fr)
EP (3) EP3973982B1 (fr)
JP (2) JP6856819B2 (fr)
KR (2) KR20200045543A (fr)
CN (2) CN111050787A (fr)
AR (1) AR112541A1 (fr)
AU (1) AU2018326556B2 (fr)
BR (1) BR112020003379A2 (fr)
CA (1) CA3073624A1 (fr)
CL (1) CL2020000482A1 (fr)
DK (2) DK3973982T3 (fr)
EA (1) EA202090480A1 (fr)
ES (2) ES2904787T3 (fr)
FI (1) FI3973982T3 (fr)
HR (2) HRP20241171T1 (fr)
HU (2) HUE068024T2 (fr)
IL (1) IL272763B2 (fr)
JO (1) JOP20200034B1 (fr)
LT (2) LT3675894T (fr)
MA (2) MA56224B1 (fr)
MD (2) MD3973982T2 (fr)
MX (2) MX2020002235A (fr)
MY (1) MY200791A (fr)
PH (1) PH12020500404A1 (fr)
PL (2) PL3973982T3 (fr)
PT (2) PT3675894T (fr)
RS (2) RS62810B1 (fr)
SG (1) SG11202003840QA (fr)
SI (2) SI3675894T1 (fr)
TW (1) TWI749255B (fr)
UA (1) UA126869C2 (fr)
WO (1) WO2019043143A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418107A (zh) * 2000-01-27 2003-05-14 应用研究系统Ars股份公司 用于治疗不孕症的卵泡刺激激素(fsh)的应用
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2700335C (fr) * 2007-09-21 2015-12-01 Pharmabrand S.A. Composition comportant des polysaccharides mucilagineux derives de alde barbadensis combines a des liposomes, methode pour l'obtenir et utilisation de celle-ci comme ecran solaire, agent anti-acne, regenerateur d'epiderme ou hydratant
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
EP2526111A2 (fr) * 2010-01-21 2012-11-28 Ramot at Tel Aviv University, Ltd. Dérivés d'aloé-émodine et leur utilisation pour le traitement du cancer
EP2621517B2 (fr) 2010-09-29 2023-10-11 Ferring B.V. Composition pour la utilisation dans le traitement de l'infertilité
EP2717904A1 (fr) 2011-06-06 2014-04-16 Ferring BV Préparation pharmaceutique
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) * 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino
MD3261661T2 (ro) 2015-02-26 2024-04-30 Ferring Bv Menotropină pentru tratarea infertilității
EP3662925B1 (fr) * 2015-04-17 2021-04-07 Ferring B.V. Composition comprenant de la fsh pour le traitement de la stérilité
LT3286209T (lt) 2015-04-24 2021-02-25 Ferring Bv Gonadotropino gamybos būdas
WO2016207353A1 (fr) 2015-06-26 2016-12-29 Ferring B.V. Procédés de purification et/ou d'inactivation virale
RS66871B1 (sr) 2018-04-30 2025-06-30 Ferring Bv Kompozicija za kontrolisanu stimulaciju jajnika
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
IL272763B2 (en) 2024-02-01
PT3973982T (pt) 2024-09-16
US20200197493A1 (en) 2020-06-25
DK3675894T3 (da) 2022-01-24
MY200791A (en) 2024-01-16
WO2019043143A1 (fr) 2019-03-07
TW201919687A (zh) 2019-06-01
MD3675894T2 (ro) 2022-03-31
KR20200045543A (ko) 2020-05-04
AU2018326556A1 (en) 2020-03-05
EP4427806A2 (fr) 2024-09-11
RS62810B1 (sr) 2022-02-28
PL3973982T3 (pl) 2024-11-04
HRP20241171T1 (hr) 2024-11-22
MX2024009224A (es) 2024-08-06
BR112020003379A2 (pt) 2020-08-25
EP4427806A3 (fr) 2024-10-09
CN111050787A (zh) 2020-04-21
JP2020528071A (ja) 2020-09-17
TWI749255B (zh) 2021-12-11
JOP20200034B1 (ar) 2024-04-18
EP3675894B1 (fr) 2021-11-03
MA56224A (fr) 2022-04-20
PT3675894T (pt) 2022-01-25
JP2021046398A (ja) 2021-03-25
SI3973982T1 (sl) 2024-10-30
SI3675894T1 (sl) 2022-01-31
EP3675894A1 (fr) 2020-07-08
CL2020000482A1 (es) 2020-06-26
HUE068024T2 (hu) 2024-12-28
US11744879B2 (en) 2023-09-05
ES2904787T3 (es) 2022-04-06
RS65945B1 (sr) 2024-10-31
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
US20240024424A1 (en) 2024-01-25
LT3973982T (lt) 2024-09-10
AR112541A1 (es) 2019-11-06
MD3973982T2 (ro) 2024-11-30
CN120617484A (zh) 2025-09-12
KR20250078595A (ko) 2025-06-02
UA126869C2 (uk) 2023-02-15
FI3973982T3 (fi) 2024-09-23
EP3973982B1 (fr) 2024-07-31
MA56224B1 (fr) 2024-09-30
MA50034A (fr) 2021-05-12
ES2989511T3 (es) 2024-11-26
DK3973982T3 (da) 2024-09-23
SG11202003840QA (en) 2020-05-28
HUE056726T2 (hu) 2022-03-28
AU2018326556B2 (en) 2024-09-26
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
MX2020002235A (es) 2020-07-20
JP6856819B2 (ja) 2021-04-14
JOP20200034A1 (ar) 2020-02-13
CA3073624A1 (fr) 2019-03-07
PH12020500404A1 (en) 2021-03-01
EP3973982A1 (fr) 2022-03-30
IL272763A (en) 2020-04-30
HRP20211802T1 (hr) 2022-03-04
JP7373479B2 (ja) 2023-11-02

Similar Documents

Publication Publication Date Title
GEP20257840B (en) Tyk2 pseudokinase ligands
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EP4582144A3 (fr) Agents, utilisations et méthodes pour le traitement de la synucléinopathie
MA49760B1 (fr) Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique
MX2018015684A (es) Composiciones y metodos para el agotamiento de celulas cd117.
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
EP4421094A3 (fr) Agents thérapeutiques ciblés et leurs utilisation
PH12021552763A1 (en) Treatment and prevention of metabolic diseases
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
MA46548B1 (fr) Fsh pour le traitement de l'infertilité
EA201991147A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
JOP20180127A1 (ar) صيغ صلبة من منشط محلقة غوانيليل قابل للذوبان (sGC)
BR112022010905A2 (pt) Formulações de anticorpos anti-cd38 para administração subcutânea
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
NZ762312A (en) Anti-pacap antibody
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
EP4566629A3 (fr) Utilisation d'un échange de plasma à faible volume pour le traitement de la maladie d'alzheimer dans des stades précoces et intermédiaires
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2024002069A (es) Anticuerpos anti-hla-g.
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MX2022011564A (es) Tratamiento del dolor.
MA50034B1 (fr) Composition de stimulation ovarienne contrôlée
MX2020010425A (es) Composicion isotopicamente modificada y sus usos terapeuticos.